Sector News

Reuters: Rare disease drugmaker PTC Therapeutics explores sale – sources

February 25, 2015
Life sciences
(Reuters) – Rare disease drugmaker PTC Therapeutics Inc (PTCT.O) is exploring a potential sale amid takeover interest from several pharmaceutical companies, including Shire Plc (SHP.L) and BioMarin Pharmaceutical Inc (BMRN.O), according to people familiar with the matter.
 
The company, which treats a muscle-wasting disorder known as Duchenne, is working with financial advisers as it weighs strategic alternatives, said the sources, who asked not to be named because the matter is private.
 
Representatives for South Plainfield, New Jersey-based PTC Therapeutics could not be reached for comment. Representatives for Shire and BioMarin declined to comment.
 
The stock of PTC Therapeutics, which has a market valuation of roughly $2 billion, rose as much as 25 percent to $68.44 on reports of the potential sale, before easing to $63.51, up 15.1 percent.
 
Makers of treatments for rare diseases, also known as orphans, are attractive acquisitions for large pharmaceutical companies looking to offset a drop in sales as patents on their blockbuster products expire.
 
Prosena Holding NV, which also makes a treatment for Duchenne, was acquired last November by BioMarin for $840 million.
 
PTC Therapeutics’ drug Translarna has received orphan drug status in the European Union and the United States and is in process of seeking U.S. Food and Drug Administration approval.
 
Shire Plc could be interested in acquiring PTC Therapeutics to add to its portfolio of rare disease drugs, the sources added.
 
Shire has made several acquisitions to bolster its focus on rare diseases, including a $5.2 billion purchase of NPS Pharmaceuticals in January and a $4.2 billion deal for ViroPharma last year.
 
It also took a look at acquiring Salix Pharmaceuticals Ltd (SLXP.O) in recent weeks but ended up passing on the deal, according to sources.
 
(Reporting by Olivia Oran and Soyoung Kim in New York; Editing by Christian Plumb and Jeffrey Benkoe)

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.